Clinical trials: Visually Impaired Persons
Xerophthalmia
Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops
The objective is to evaluate the safety, local tolerability, and pharmacokinetics of NCP112 eye drops through single and multiple dose-escalation ocular administrations in healthy adults.
- Trial name
- NCT06263998
- Testing
- NCP112
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Hereditary Angioedema (HAE)
Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects
This trial is looking to gain information about the safety and tolerability of an investigational treatment (SHP623) in healthy adult volunteers.
- Trial name
- NCT02663687
- Testing
- Recombinant human C1 esterase inhibitor, SHP623
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shire
Digestion, GI Health
Radicle GI HealthTM VKP: A Study Assessing the Impact of Health and Wellness Products on Gastrointestinal-related Quality of Life and Related Health Outcomes
Radicle GI Health VKP: A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on gastrointestinal-related quality of life and related health outcomes.
- Trial name
- NCT07873216
- Testing
- Active GI Health Product
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Fabry Disease
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
GR181413A/AT1001 (migalastat hydrochloride) is a low molecular weight iminosugar, an analog of the terminal galactose group that is cleaved from the substrate GL-3.
- Trial name
- NCT01853852
- Testing
- GR181413A/AT1001 solution, GR181413A/AT1001 capsule, Potable water
- Where
- Australia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants
This research project is being conducted to investigate the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) and multiple ascending doses (MAD) of oral ETX0282 when administered alone and in…
- Trial name
- NCT03491748
- Testing
- ETX0282, Cefpodoxime proxetil
- Where
- Australia
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Entasis Therapeutics
Gastroenteritis Escherichia Coli, Immunisation
A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area
This is a trial to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by oral, sublingual, or intradermal vaccination in approximately 135…
- Trial name
- NCT03548064
- Testing
- Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Where
- 2 sites in United States, Bangladesh
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Long QT Syndrome
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.
- Trial name
- NCT02365532
- Testing
- GS-6615, Dofetilide
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus
Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023
The purpose of this study is to investigate the safety and pharmacokinetics of KM-023 after single/multiple dosing.
- Trial name
- NCT01348516
- Testing
- KM-023
- Where
- South Korea
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Kainos Medicine Inc.
Rhinitis, Allergic, Seasonal
Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects
This is a double-blind, placebo-controlled, randomized single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose study to investigate safety, tolerability and…
- Trial name
- NCT00694993
- Testing
- GSK1004723
- Where
- Germany
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
A Phase 1 Study of S-1117
This is the first-in-human study of S-1117 designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers.
- Trial name
- NCT06828393
- Testing
- S-1117
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Seismic Therapeutic AU Pty Ltd
Serious Infections Due to Known or Suspected Gram-positive Pathogens
TD-1607 SAD Study in Healthy Subjects
TD-1607, administered intravenously as single doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.
- Trial name
- NCT01791049
- Testing
- TD-1607
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
BCG Vaccination Reaction, Tuberculosis
A Study of GC3107(BCG Vaccine) in Healthy Infants
The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants
- Trial name
- NCT03947138
- Testing
- GC3107, Intradermal BCG SSI inj.
- Where
- 2 sites in South Korea
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Ebola Virus Disease, Hemorrhagic Fever
Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02368119
- Testing
- VRC-EBOADC069-00-vp, MVA-EbolaZ
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Moderate to Severe Convexity of Submental Fat, Safety
Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat
The objectives of this study are to explore the safety and efficacy of subcutaneous injections of Deoxycholic Acid relative to placebo, in the submental area in patients with mild or extreme fullness of the submental fat and…
- Conditions
- Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
- Trial name
- NCT02035267
- Testing
- Deoxycholic Acid
- Where
- 8 sites in United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Rabies Human, Antibody
Prevention of Rabies With Four Doses of Rabies Vaccine
To evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program over the five dose immunization program and the batches consistency of immunogenicity according…
- Trial name
- NCT05545371
- Testing
- immunization procedures
- Where
- China
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Changchun Zhuoyi Biological Co., Ltd
Influenza
Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
To evaluate the immunogenicity of administering one dose of influenza virus split vaccine (0.7mL/dose) to individuals aged 60 and above.
- Trial name
- NCT07327398
- Testing
- Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Healthy Volunteers
Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety, tolerability and pharmacokinetics (PK) of ascending doses of XC243 after single and multiple oral administration in healthy volunteers.
- Trial name
- NCT05628116
- Testing
- XC243 50 mg single, XC243 100 mg single, XC243 200 mg single-dose food effect
- Where
- Russia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- PHARMENTERPRISES LLC
Healthy Volunteer
A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects
This study is a Phase 1, randomized, double-blind, placebo-controlled study of multiple doses of SAGE-718 using ketamine challenge to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects.
- Trial name
- NCT03844906
- Testing
- SAGE-718
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Tinea Cruris, Jock Itch
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.
- Trial name
- NCT00750152
- Testing
- NAFT-500
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Merz North America, Inc.
Healthy Volunteers
A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry
This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD2373 in healthy male participants of…
- Trial name
- NCT05351047
- Testing
- AZD2373 subcutaneous injection
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.